- Previous Close
43.08 - Open
43.06 - Bid 42.66 x --
- Ask 42.67 x --
- Day's Range
42.53 - 43.41 - 52 Week Range
35.51 - 57.53 - Volume
26,575,159 - Avg. Volume
44,004,068 - Market Cap (intraday)
272.192B - Beta (5Y Monthly) 0.29
- PE Ratio (TTM)
49.62 - EPS (TTM)
0.86 - Earnings Date Oct 25, 2024
- Forward Dividend & Yield 0.20 (0.46%)
- Ex-Dividend Date Jul 12, 2024
- 1y Target Est
--
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, develops, manufactures, and commercializes drugs worldwide. The company is developing Camrelizumab, Pyrotinib, Fuzuloparib, Adebrelimab, Rezvilutamide, Famitinib, Dalpiciclib, SHR-1701, SHR-1501, SHR-A1811, SHR1459, Mecapegfilgrastim, Apatinib, Linperlisib, and SHR2554 for oncology indications; SHR4640, Retagliptin, SHR20004, SHR-1209, SHR3824, INS068, SHR7280, and SHR2285 for cardiovascular and metabolism indications. It is also developing SHR0302, Hetrombopag, Vunakizumab, and SHR-1703 for autoimmune indications; SHR0410, Imrecoxib, Remimazolam, and SHR8554 for pain; Oteseconazole and HRS9950 for anti-infection; and SHR8028, SHR8058, SHR-1707, and SHR-1222 for other indications. The company was founded in 1970 and is based in Lianyungang, China.
www.hrs.com.cn19,611
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 600276.SS
View MorePerformance Overview: 600276.SS
Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 600276.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 600276.SS
View MoreValuation Measures
Market Cap
274.81B
Enterprise Value
251.99B
Trailing P/E
50.09
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.50
Price/Book (mrq)
6.28
Enterprise Value/Revenue
9.69
Enterprise Value/EBITDA
42.38
Financial Highlights
Profitability and Income Statement
Profit Margin
20.96%
Return on Assets (ttm)
7.48%
Return on Equity (ttm)
12.88%
Revenue (ttm)
26B
Net Income Avi to Common (ttm)
5.45B
Diluted EPS (ttm)
0.86
Balance Sheet and Cash Flow
Total Cash (mrq)
22.91B
Total Debt/Equity (mrq)
0.20%
Levered Free Cash Flow (ttm)
5.56B